News

TreeFrog raises further funds

Country
France

The French cell therapy start-up, TreeFrog Therapeutics SAS, has raised a further €3 million in funding for its stem cell production technology, only months after a €7.1 million Series A financing round. Based in Bordeaux, TreeFrog has a platform for mass producing stem cells, reportedly at a significantly lower cost than existing methods.

The platform uses a three-dimensional cell culture system to produce stem cells in bioreactors with short lead times. The new funding includes €450,000 from the French government and €2.4 million from the EU’s Horizon 2020 programme.

Meeting Report: CAR therapy delivers

Country
Belgium

Emily Whitehead celebrated her 14th birthday in May, which was also the seventh year she has been free of cancer. The complete remission of her cancer - acute lymphoblastic leukaemia – is the first of many successes of the immunotherapy, chimeric antigen receptor (CAR) T cells, which are experiencing an expositive growth around the world.

Positive opinion for Xospata in AML

Country
Netherlands

The European Medicines Agency has issued a positive opinion for the personalised therapy Xospata (gilteritinib) to treat acute myeloid leukaemia (AML) following approvals for the same drug in both the US and Japan. The developer is Tokyo-based Astellas Pharma Inc.

Xospata is being recommended as a monotherapy for the treatment of adult patients with relapsed or refractory AML with a FLT3 gene mutation. The positive opinion will need to be adopted by the European Commission before Xospata can be marketed.

Lundbeck to acquire Alder

Country
Denmark

H. Lundbeck A/S is to acquire the US biopharmaceutical company Alder BioPharmaceuticals Inc in order to add migraine to its disease coverage and build expertise in monoclonal antibody technology. The transaction is valued at up to $1.95 billion net of cash.

Data disclosed for RNA enzyme inhibitor

Country
United Kingdom

Storm Therapeutics Ltd has disclosed data from an animal study of a new small molecule inhibitor of an RNA modifying enzyme which showed activity against cancer. The study results were announced on 18 September at a meeting in Cambridge, UK attended by scientists from Europe and the US who are at the forefront of the new science of RNA epigenetics.

RNA epigenetics describes the chemical markers on messenger RNA that carry genetic information from DNA to a cell’s protein-manufacturing factories. When this process is modified by enzymes it can lead to disease.

BACE inhibitor trial stopped on safety

Country
United States

Safety concerns once again triggered the stoppage of a late-stage Alzheimer’s disease trial with a BACE inhibitor, a small molecule drug intended to limit amyloid-beta production. Eisai Co Ltd and Biogen Inc announced the discontinuation of two studies with elenbecestat on 13 September following a review by the trials’ data safety monitoring board.

Academic collaborations for Crescendo

Country
United Kingdom

Crescendo Biologics Ltd has entered into collaborations with two UK universities to accelerate development of its lead product for tumours expressing prostate-specific membrane antigen (PSMA). The product, CB307, is due to enter the clinic in 2020.

Separately Crescendo appointed Steward Kay, formerly of GlaxoSmithKline Plc, as its chief business officer.

New EU drug discovery fund launched

Country
Belgium

The European Investment Fund (EIF), together with institutions in Germany and Austria, has launched a new fund to support early-stage drug discovery projects sourced predominantly from academic institutions in both countries.

The fund, KHAN Technology Transfer Fund I GmbH (KHAN-I), is based in Dortmund, Germany and has capital of €60 million. Half of the initial capital, or €30 million, is being provided by the EIF, which is part of the European Investment Bank Group. The fund will invest in either new project ideas covered by collaboration agreements or in start-up companies.

Morningside Ventures leads funding for Inotrem

Country
France

A French immunology company founded in 2013 has raised €39 million in a Series B financing round to advance the development of a drug candidate for patients with septic shock. Inotrem SA is being supported by Morningside Ventures, which led the round, along with the evergreen investor Invus. Existing investors Andera Partners, Sofinnova Partners and BiomedInvest, also participated in the round.

Gates Foundation invests in BioNTech

Country
Germany

The Bill & Melinda Gates Foundation is to make a $55 million equity investment in BioNTech SE as part of a collaboration aimed at developing potential HIV and tuberculosis vaccine and immunotherapy candidate drugs. Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation. The additional funds would be used to underwrite the evaluation of the candidate products in the clinic and to start new infectious disease projects.